Bayer · company speakers →
brought attention to BAY 3547926, an antibody-based radionuclide therapy that targets glypican-3 (GPC3)-positive liver cancer cells and delivers alpha radiation-emitting Actinium-225.
Is this you? Claim this profile →
No public contact links on file.
Sourcing speakers for your event?
Browse the speaker directory →